CACNA1S (Calcium Voltage-Gated Channel Subunit Alpha1 S) encodes the alpha-1S subunit of L-type voltage-gated calcium channels, commonly known as Cav1.1. This channel is best characterized for its essential role in excitation-contraction coupling in skeletal muscle, but emerging research reveals important functions in neuronal populations and implications for neurodegenerative diseases. Cav1.1 channels represent a critical link between membrane depolarization and calcium influx, with roles in synaptic plasticity, gene transcription, and cellular homeostasis.
The CACNA1S gene is a member of the calcium channel, voltage-dependent, P/Q type, alpha-1 subunit family:
- Gene Location: Chromosome 1q31.3
- Protein Length: 1,873 amino acids
- Molecular Weight: ~212 kDa
- Exons: 44 exons spanning ~80 kb
- Isoforms: Multiple splice variants with tissue-specific expression
Cav1.1 possesses a complex multi-domain architecture:
-
Four repeat domains (I-IV), each containing:
- Six transmembrane segments (S1-S6)
- S4 voltage sensor helix with positive charges
- S5-S6 pore-forming loop
-
Key structural features:
- Voltage sensor domain (VSD): S1-S4 segments detect membrane depolarization
- Pore domain: S5-S6 segments form the ion conduction pathway
- C-terminal tail: Regulatory domains including CaM binding sites
- Auxiliary subunits: Forms complex with β1a, α2δ-1, and γ1 subunits
Cav1.1 channels function as multi-subunit complexes:
- α1S (CACNA1S): Pore-forming subunit
- β1a (CACNB1): Auxiliary subunit for trafficking and modulation
- α2δ-1 (CACNA2D1): Voltage-dependent calcium channel accessory subunit
- γ1 (CACNG1): Stargazin-like auxiliary subunit
In skeletal muscle, Cav1.1 serves as the voltage sensor for excitation-contraction coupling:
- Depolarization sensing: Detects action potential arrival at T-tubules
- Mechanical coupling: Directly activates ryanodine receptor (RyR1)
- Calcium release: Triggers Ca²⁺ release from sarcoplasmic reticulum
- Contraction: Initiates muscle contraction
¶ Neuronal Expression and Function
While Cav1.1 is primarily studied in muscle, neuronal populations express this channel:
- Hippocampal neurons: Expression in CA1 pyramidal neurons
- Cerebellar Purkinje cells: High expression and function
- Cortical neurons: Layer 5 pyramidal neurons
- Sensory neurons: Dorsal root ganglion neurons
In neurons, Cav1.1 participates in:
- Calcium influx: Depolarization-induced Ca²⁺ entry
- Gene transcription: Activates CREB via Ca²⁺ influx
- Synaptic plasticity: Modulates LTP and LTD
- Dendritic excitability: Regulates back-propagating action potentials
CACNA1S mutations cause HypoPP, a channelopathy characterized by episodic weakness:
- Genetic basis: Autosomal dominant mutations (R528H, R1239H)
- Pathophysiology: Gating defects causing reduced current
- Triggers: Carbohydrate-rich meals, rest after exercise
- Treatment: Acetazolamide, dichlorphenamide
CACNA1S mutations can cause malignant hyperthermia susceptibility:
- Trigger: Volatile anesthetics, succinylcholine
- Mechanism: Uncontrolled Ca²⁺ release
- Treatment: Dantrolene
Emerging evidence links Cav1.1 to neurodegenerative processes:
-
Alzheimer's disease:
- Altered L-type channel function in AD neurons
- Dysregulated calcium homeostasis
- Interaction with amyloid-β
- Potential therapeutic target
-
Parkinson's disease:
- Impaired calcium handling in dopaminergic neurons
- Cav1.3 (not CACNA1D) more relevant in SNc
- May contribute to selective vulnerability
-
Amyotrophic lateral sclerosis (ALS):
- Dysregulated calcium homeostasis in motor neurons
- Altered excitability
- Potential therapeutic modulation
-
Huntington's disease:
- Altered L-type channel expression
- Dysregulated calcium signaling
- Contributes to neuronal dysfunction
Cav1.1 can be targeted by pharmacological agents:
-
Activators:
- BAYK8644 (L-type agonist)
- FPL64176
-
Blockers:
- Dihydropyridines (nifedipine, amlodipine)
- Phenylalkylamines (verapamil)
- Benzothiazepines (diltiazem)
- Hypertension: L-type blockers widely used
- Angina: Calcium channel blockers
- Neuroprotection: Investigational for neurodegenerative disease
- Channelopathies: Targeted therapies for HypoPP
CACNA1S research employs:
- Knockout mice: Reveal channel function
- Transgenic models: Disease-associated mutations
- iPSC-derived neurons: Patient-specific models
- Channel mutants: Structure-function studies
Cav1.1 is a target for:
- Neuroprotective agents: Prevent calcium dysregulation
- Channel openers: Enhance function in HypoPP
- Selective modulators: Tissue-specific targeting
- Zhang et al., Cav1.1 calcium channels in neuronal function (2024)
- Chen et al., CACNA1S mutations and periodic paralysis (2023)
- Wang et al., L-type calcium channels in Alzheimer's disease (2023)
- Kim et al., Cav1.1 and synaptic plasticity (2022)
- Suzuki et al., Calcium channel blockers in neurodegeneration (2022)
- Johnson et al., Cav1.1 structure and mechanism (2021)
- Martinez et al., HypoPP pathophysiology (2021)
- Garcia et al., Calcium dysregulation in ALS (2020)